Our RESETTM clinical trials with CABA-201 (investigational CD19-CAR T cell therapy) in lupus, myositis, systemic sclerosis, myasthenia gravis, and pemphigus vulgaris are now recruiting.
Are You an Eligible Patient?
A Phase 1/2 Open Label Study of Autologous CD19-Specific Chimeric Antigen Receptor T Cells (CABA-201) in Generalized Myasthenia Gravis, Sponsored by Cabaletta Bio, Inc.
Learn more about our Phase 1/2 study in generalized myasthenia gravis through our clinical trial page at ClinicalTrials.gov.
Contact Us
Are you wondering if this clinical trial is right for you? To find out more, contact the study team using the information below.
Learn About Myasthenia Gravis
What is myasthenia gravis?
MG is an autoimmune disease that results from antibodies, or proteins produced by the immune system, that get in the way of signals between nerves and muscles. It is unclear why the body’s immune system behaves this way, but these antibodies are thought to be made by B cells, a type of white blood cell in the immune system. These antibodies can directly block the communication between nerves and muscles, causing disease symptoms that are associated with MG, such as weakness.
Learn About Our Trial
What is a clinical trial?
A clinical trial is designed to evaluate whether an investigational treatment is safe and effective for use in humans.
What is Cabaletta’s RESET-MG trial?
RESET-MG is a phase 1/2 clinical trial being conducted to evaluate the effects of the investigational cell treatment CABA-201 in patients with generalized myasthenia gravis (MG) who have active disease.
What is CABA-201?
CABA-201 is the investigational treatment used in the RESET-MG study. This clinical trial evaluates the safety, tolerability and effectiveness of CABA-201 in the treatment of myasthenia gravis.
CABA-201 is an investigational chimeric antigen receptor (CAR) T cell therapy designed to treat myasthenia gravis by targeting the B cells that may be causing the disease.
CABA-201 is made from your own T cells, a type of white blood cell, and uses your own immune system to get rid of the disease-causing B cells and to restore healthy B cells in your body.
Who can participate in Cabaletta’s RESET-MG trial?
You or someone you know may be eligible to participate if you:
- Are 18 to 70 years of age.
- Have a diagnosis of generalized myasthenia gravis which is not improving or is getting worse after trying to control it with other treatments.
Additional requirements will apply, and only a study doctor can determine eligibility to participate in the study. Sites involved in the study are listed at ClinicalTrials.gov.
Why participate in this study?
By participating in the RESET-MG study, you will:
- Play an important role in understanding myasthenia gravis.
- Receive study-related care, tests and procedures from a study doctor at no cost to you.
- Receive compensation for your time during certain study visits and reimbursement for reasonable travel expenses.
What are the potential risks of participating in this trial?
Therapy with CAR T cells may cause serious and potentially life-threatening side effects. The potential risks of participating in this clinical trial will be explained to you before you decide whether to participate.